BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $55

Moomoo News16minutes ago · Ratings

Agios Pharmaceuticals Price Target Lowered to $55 From $60 at BofA

TipRanks29minutes ago

Express News | Agios Pharmaceuticals - to Discontinue Pyrukynd if Hepatic Injury Due to Pyrukynd Is Suspected

ReutersJan 6 06:40 ET

Express News | Agios Pharmaceuticals - Uspi Sections Updated to Include Liver Injury Information

ReutersJan 6 06:38 ET

Express News | Agios Pharmaceuticals - FDA Approves Update to Uspi for Pyrukynd for Hemolytic Anemia

ReutersJan 6 06:38 ET

How to Navigate the Stock and Bond Markets in 2025 -- Journal Report

Dow JonesJan 3 10:00 ET